The drug developer, which is targeting chronic inflammation-related diseases, has raised series A cash two years after it spun out of Selvita.
NodThera, a UK-based developer of treatments for diseases caused by chronic inflammation, which counts drug discovery services provider Selvita as a backer, completed a £28m ($37m) series A round on Monday.
Venture capital firms Sofinnova Partners and 5AM Ventures co-led the round, investing together with F-Prime Capital Partners, branch of investment and financial services group Fidelity, and Epidarex Capital, which provided seed capital for the company in 2016.
NodThera is working on therapies for inflammation-related diseases, and in particular an…
